CYChoa Yun

Choa Yun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Choa Yun has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunoproteomic Profiling of Autoantibodies and Antibodies against Infectious Agents in Autoimmune Diseases

    by Choa Yun, Ji Qiu, M. Constanza Camargo, Lusheng Song, Joshua LaBaer, Hyokyoung G. Hong, Maddy Edie-Booker, Byunghyun Kang, Ilze Konrade, Adam Schiffenbauer, et al.

    Prior research investigated limited antibody sets within individual autoimmune diseases. Using the Nucleic-Acid Programmable Protein Array platform, we measured antibodies against 280 human, 40 viral, and 15 bacterial antigens in serum from 237 patients with 8 autoimmune diseases, including autoimmune gastritis (AG), autoimmune thyroiditis (AT), celiac disease (CD), idiopathic inflammatory myopathies (IIM), type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE), and 112 controls. Candidate antibodies were identified by combining Firth logistic regression and machine learning. We identified disease-specific antibodies, ranging from 3 in IIM to 13 in SLE for IgG and 1 in CD to 13 in AG for IgA. Additionally, 63 IgG and 44 IgA antibodies were shared across two or more diseases. Notably, two IgG autoantibodies overlapped in up to five diseases: directed against STNM4 (SLE, SjD, T1D, CD, and RA) and TRIM21 (SLE, SjD, IIM, CD, and RA); and three IgA antibodies in up to seven diseases: directed against H1N1 Influenza A virus NP (IIM, SjD, AG, T1D, CD, RA, and AT) and Coxsackievirus B3MK012537 and Enterovirus C PVgp1 (IIM, SjD, AG, T1D, CD, SLE, and RA). These findings underscore the potential of antibody profiling in autoimmune disease characterization and biomarker discovery.

  • Open Access

    The Interplay of Inherited Chromosomally Integrated Human Herpesvirus 6, Telomere Length, and the Metabolome in Autoimmune Disease Incidence: Evidence from the UK Biobank Study

    by May Beydoun, Minkyo Song, Choa Yun, Hind A. Beydoun, Nigus G. Asefa, Jordan Weiss, Nicole Noren Hooten, Michele K. Evans, Alan B. Zonderman

    Autoimmune diseases arise from failures in immune regulation and increase with biological aging. Inherited chromosomally integrated human herpesvirus-6 (iciHHV-6) represents a unique model of lifelong viral exposure, as the viral genome is embedded within host telomeres and may influence leukocyte telomere length (LTL), a marker of immune aging. Circulating metabolites may further shape these viral-telomeric interactions. Using 156,927 UK Biobank participants free of autoimmune disease at baseline, we examined associations between iciHHV-6, LTL, and incident autoimmune disease, and evaluated metabolomic pathways that mediate or modify these relationships. Over follow-up, autoimmune disease incidence was 7.8%, and iciHHV-6 prevalence was 1.3%. iciHHV-6 carrier status was not directly associated with autoimmune disease risk despite higher comorbidity burden. Longer LTL was independently protective overall, particularly for rheumatoid arthritis, although it was positively associated with multiple sclerosis. iciHHV-6 carriers exhibited longer LTL, resulting in a small but significant indirect protective effect on autoimmune disease risk. LTL also moderated viral effects, with stronger protection among iciHHV-6-positive individuals, suggesting telomere length buffers adverse viral-immune interactions. Metabolomic analyses revealed that triglyceride-rich lipoproteins and pro-inflammatory lipids were associated with shorter LTL and higher autoimmune risk, whereas omega-3 fatty acids, albumin, and HDL phospholipids were protective. Lipidomic pathways mediated a meaningful proportion of the LTL-autoimmune association and modified viral effects. Together, these findings support a telomere-lipid-immunity axis linking viral integration, metabolic aging, and autoimmune susceptibility.

  • Open Access

    Immune responses to infection and autoimmune diseases in the UK biobank

    by Choa Yun, Dongwon Yoon, Sun-Young Jung, Moonsuk Kim, May A. Beydoun, Lenore Launer, Minkyo Song


  • Open Access

    Regional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model

    by Minah Park, Choa Yun, Jae Hong Joo, Soo Hyun Kang, Sung Hoon Jeong, Chung-Mo Nam, Eun-Cheol Park, Yoondae Han, Sung In Jang

    Background: There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. Objective: This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. Methods: This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. Results: Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. Conclusions: Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.


  • Open Access

    The Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea

    by Dong-Gon Hyun, Jee Hwan Ahn, Ha-Yeong Gil, Chung Mo Nam, Choa Yun, Jae-Myeong Lee, Jae Hun Kim, Dong-Hyun Lee, Ki Hoon Kim, Dong Jung Kim, et al.

    Hyun DG, et al. J Korean Med Sci. 2023 Apr;38(19):e141. https://doi.org/10.3346/jkms.2023.38.e141


  • Open Access

    Regional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model (Preprint)

    by Minah Park, Choa Yun, Jae Hong Joo, Soo Hyun Kang, Sung Hoon Jeong, Chung-Mo Nam, Eun-Cheol Park, Yoondae Han, Sung In Jang

    BACKGROUND There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. OBJECTIVE This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. METHODS This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. RESULTS Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. CONCLUSIONS Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.